Effects of Glucagon-like Peptide-1 Receptor Agonists and Sodium-glucose Cotransporter 2 Inhibitors on Cardiorenal and Metabolic Outcomes in People Without Diabetes

Author(s): Athanasia K. Papazafiropoulou*, Andreas Melidonis, Stavros Antonopoulos

Journal Name: Current Pharmaceutical Design

Volume 27 , Issue 8 , 2021

Become EABM
Become Reviewer
Call for Editor


During the last decade, the results of large-scale, randomized, clinical trials on newer antidiabetic agents, glucagon-like peptide-1 (GLP-1) receptor agonists and sodium glucose cotransporter type 2 (SGLT2) inhibitor, have been published showing promising findings on cardiovascular and renal outcomes. Besides improving glycemic control, GLP-1 receptor agonists have been shown to modify cardiovascular risk factors, such as insulin resistance, body weight, blood pressure (BP), and lipid profile. Additionally, SGLT2 inhibitors except for glycemic control have been shown to induce weight loss and decrease BP. However, there are limited data regarding their effect on patients without diabetes. Therefore, the aim of the present review is to summarize the existing literature data regarding the effects of newer antidiabetic therapies on patients without diabetes.

Keywords: Non-diabetic, SGLT2 inhibitors, GLP-1 receptor agonists, empagliflozin, dapagliflozin, canagliflozin, liraglutide, dulaglutide, exenatide, semaglutide.

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2021
Published on: 08 April, 2021
Page: [1035 - 1042]
Pages: 8
DOI: 10.2174/1381612826666200909142126
Price: $65

Article Metrics

PDF: 150